• Kancera AB, of Stockholm, Sweden, said its ROR inhibitors showed an effect in a model of human pancreatic cancer. The compounds were superior in efficacy to gemcitabine. The study was done in collaboration with Matthias Lohr, a professor at the Karolinska Institutet in Stockholm.